

Taofeek Kunle Owonikoko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6092264/publications.pdf>

Version: 2024-02-01

228
papers

16,648
citations

27035

58
h-index

20625

120
g-index

232
all docs

232
docs citations

232
times ranked

27295
citing authors

#	ARTICLE	IF	CITATIONS
1	Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. <i>Oncogene</i> , 2022, 41, 1691-1700.	2.6	9
2	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1540-1548.	3.2	21
3	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. , 2022, 10, e004273.		10
4	Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. <i>Cell</i> , 2022, 185, 1974-1985.e12.	13.5	17
5	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. <i>Cancers</i> , 2022, 14, 2639.	1.7	4
6	MERTK activation drives osimertinib resistance in EGFR-mutant nonâ€“small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
7	Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEERâ€“Medicare Database Analysis. <i>Cancers</i> , 2022, 14, 3206.	1.7	4
8	Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. <i>Future Oncology</i> , 2022, 18, 2639-2649.	1.1	14
9	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cellâ€“Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 464-476.	0.5	93
10	Benefits and limitations of real-world evidence: lessons from <i>EGFR</i> mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 965-977.	1.1	40
11	A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 240-244.	7.7	10
12	Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Advances in Therapy</i> , 2021, 38, 350-365.	1.3	71
13	Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. <i>Theranostics</i> , 2021, 11, 3964-3980.	4.6	15
14	Optimum health and inhibition of cancer progression by microbiome and resveratrol. <i>Frontiers in Bioscience - Landmark</i> , 2021, 26, 496-517.	3.0	5
15	Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/Ia studies in patients with extensive-stage small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 689-700.	1.1	9
16	An expanded universe of cancer targets. <i>Cell</i> , 2021, 184, 1142-1155.	13.5	135
17	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021, 39, 1349-1359.	0.8	147
18	Evaluating the impact of the Patient Preference Assessment Tool on clinicians' recommendations for phase I oncology clinical trials. <i>Psycho-Oncology</i> , 2021, 30, 1739-1744.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1508-e1513.	1.9	16
20	Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. <i>Clinical Cancer Research</i> , 2021, 27, 3884-3895.	3.2	40
21	Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). <i>Journal of Clinical Oncology</i> , 2021, 39, 8510-8510.	0.8	35
22	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. <i>Clinical Lung Cancer</i> , 2021, 22, 187-194.e1.	1.1	18
23	Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. <i>Molecular Cancer Research</i> , 2021, 19, 1622-1634.	1.5	19
24	Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. <i>Cancer Research</i> , 2021, 81, 4822-4834.	0.4	29
25	Physician Communication and Patient Understanding of Molecular Testing Terminology. <i>Oncologist</i> , 2021, 26, 934-940.	1.9	5
26	Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. <i>PLoS ONE</i> , 2021, 16, e0254125.	1.1	12
27	Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion. <i>Advances in Therapy</i> , 2021, 38, 5431-5451.	1.3	12
28	Discovery of Small Molecule Bak Activator for Lung Cancer Therapy. <i>Theranostics</i> , 2021, 11, 8500-8516.	4.6	19
29	Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. <i>Oncogene</i> , 2021, 40, 6653-6665.	2.6	17
30	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020, 126, 575-582.	2.0	65
31	Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. <i>Journal of Thoracic Oncology</i> , 2020, 15, 274-287.	0.5	95
32	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , 2020, 25, e528-e535.	1.9	44
33	ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. <i>Cancer</i> , 2020, 126, 1339-1350.	2.0	40
34	Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups. <i>Head and Neck</i> , 2020, 42, 678-687.	0.9	8
35	CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, e000847.		45
36	Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. <i>Lung Cancer</i> , 2020, 150, 26-35.	0.9	11

#	ARTICLE	IF	CITATIONS
37	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1228-1234.	2.9	6
38	Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 5040-5049.	2.0	12
39	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. <i>Clinical Cancer Research</i> , 2020, 26, 5860-5868.	3.2	11
40	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	13.9	454
41	Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer. <i>Oncologist</i> , 2020, 25, e1586-e1588.	1.9	0
42	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	157.7	93
43	Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. <i>Cancer Medicine</i> , 2020, 9, 7511-7523.	1.3	8
44	EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. <i>Oncogene</i> , 2020, 39, 4798-4813.	2.6	29
45	Integrating Genetic and Genomic Testing Into Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e259-e263.	1.8	6
46	MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor mutant lung cancers. <i>Cancer</i> , 2020, 126, 3788-3799.	2.0	26
47	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2497-2505.	3.2	9
48	BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degradors That Potently Induce Apoptosis through Suppression of Mcl-1. <i>Cancer Research</i> , 2020, 80, 2380-2393.	0.4	28
49	SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
50	Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1000.	1.3	152
51	Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 304-313.	0.4	42
52	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	0.5	119
53	Overcoming acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. <i>Molecular Oncology</i> , 2020, 14, 882-895.	2.1	26
54	Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. <i>Cancer</i> , 2020, 126, 3140-3150.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma. <i>Case Reports in Oncology</i> , 2020, 13, 239-244.	0.3	4
56	Overcoming acquired resistance of epidermal growth factor receptor mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). <i>Cancer</i> , 2020, 126, 2024-2033.	2.0	32
57	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. <i>Journal of Clinical Oncology</i> , 2020, 38, e001302.		34
58	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9080-TPS9080.	0.8	5
59	The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. <i>American Journal of Cancer Research</i> , 2020, 10, 3316-3327.	1.4	2
60	Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β -TrCP degradation. <i>Oncogene</i> , 2019, 38, 6270-6282.	2.6	53
61	Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6119-6126.	3.2	28
62	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1289-1301.	1.1	29
63	Mcl-1 Interacts with Akt to Promote Lung Cancer Progression. <i>Cancer Research</i> , 2019, 79, 6126-6138.	0.4	25
64	Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. <i>Annals of Oncology</i> , 2019, 30, 1613-1621.	0.6	107
65	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019, 19, 857.	1.1	88
66	Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV. <i>Frontiers in Immunology</i> , 2019, 10, 2267.	2.2	12
67	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. <i>Clinical Lung Cancer</i> , 2019, 20, 484-493.e6.	1.1	16
68	Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 3-10.	1.8	173
69	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. <i>Journal of Thoracic Oncology</i> , 2019, 14, 876-889.	0.5	141
70	Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. <i>Head and Neck</i> , 2019, 41, 1490-1498.	0.9	21
71	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 222-229.	0.8	133
72	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	1.2	11

#	ARTICLE	IF	CITATIONS
73	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. <i>PLoS ONE</i> , 2019, 14, e0206309.	1.1	7
74	Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 331-336.	0.6	5
75	The clinical conundrum of managing relapsed small cell lung cancer. <i>Cancer</i> , 2019, 125, 1022-1026.	2.0	1
76	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. <i>Cancer</i> , 2019, 125, 127-134.	2.0	120
77	Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. <i>Journal of Clinical Investigation</i> , 2019, 129, 2431-2445.	3.9	28
78	Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. <i>Journal of Clinical Investigation</i> , 2019, 129, 4110-4123.	3.9	22
79	Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9042-9042.	0.8	1
80	Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8577-TPS8577.	0.8	11
81	Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data. <i>SKIN the Journal of Cutaneous Medicine</i> , 2019, 3, 169.	0.1	1
82	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 710-716.	1.9	25
83	Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung. <i>Cancer Cytopathology</i> , 2018, 126, 236-242.	1.4	18
84	Health care disparities among octogenarians and nonagenarians with stage III lung cancer. <i>Cancer</i> , 2018, 124, 775-784.	2.0	24
85	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. <i>Cancer</i> , 2018, 124, 271-277.	2.0	265
86	The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. <i>Molecular Cell</i> , 2018, 69, 87-99.e7.	4.5	217
87	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2386-2394.	0.8	276
88	Immune checkpoint inhibitors in small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S460-S467.	0.6	46
89	Immunotherapy of lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S395-S396.	0.6	1
90	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. <i>Cancer Cell</i> , 2018, 34, 315-330.e7.	7.7	94

#	ARTICLE	IF	CITATIONS
91	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. <i>Cancer</i> , 2018, 124, 3586-3595.	2.0	5
92	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 341-351.	13.9	997
93	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , 2018, 95, 138-146.	0.9	7
94	Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. <i>Science</i> , 2017, 355, 1423-1427.	6.0	753
95	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 3476-3485.	2.0	35
96	Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, 706-718.	1.1	26
97	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4993-4998.	3.3	614
98	Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. <i>Cancer</i> , 2017, 123, 3681-3690.	2.0	36
99	Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, 551-558.e6.	1.1	24
100	P2.02-015 Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S855-S856.	0.5	0
101	OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S261-S262.	0.5	19
102	MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S406-S407.	0.5	12
103	P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results. <i>Journal of Thoracic Oncology</i> , 2017, 12, S696.	0.5	1
104	P1.07-014 Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, S703-S704.	0.5	0
105	Modulation of Bax and mTOR for Cancer Therapeutics. <i>Cancer Research</i> , 2017, 77, 3001-3012.	0.4	24
106	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. <i>Clinical Lung Cancer</i> , 2017, 18, 286-292.	1.1	64
107	Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1120.	3.4	93
108	Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. <i>Clinical Cancer Research</i> , 2017, 23, 6567-6579.	3.2	103

#	ARTICLE	IF	CITATIONS
109	Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1687-1695.	0.5	47
110	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	13.5	738
111	National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 128-137.	0.4	105
112	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 45-50.	2.0	55
113	Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile. <i>PLoS ONE</i> , 2017, 12, e0170187.	1.1	6
114	Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy. <i>Journal of Clinical Investigation</i> , 2017, 128, 500-516.	3.9	48
115	Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC) – Phase 1b results. <i>Journal of Clinical Oncology</i> , 2017, 35, 8568-8568.	0.8	7
116	A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 81441-81454.	0.8	12
117	PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2016, 11, S306-S307.	0.5	3
118	Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, e57-e64.	1.1	68
119	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 111.	1.8	78
120	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 601-611.	7.7	97
121	Better Overall Survival with Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E438-E439.	0.4	0
122	A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 1163-1164e.	1.9	32
123	Lung Stereotactic Body Radiation Therapy (SBRT) Versus Pneumonectomy in Patients With Non-Small Cell Lung Cancer (NSCLC) Ages 70 or Older. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E468.	0.4	0
124	Systemic treatment and management approaches for medullary thyroid cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 89-98.	3.4	36
125	Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. <i>Cancer Letters</i> , 2016, 380, 494-504.	3.2	137
126	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. <i>Molecular Cell</i> , 2016, 64, 859-874.	4.5	73

#	ARTICLE	IF	CITATIONS
127	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1661-1671.	5.1	115
128	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2016, 122, 766-772.	2.0	92
129	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 299-315.	1.2	55
130	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 155-162.	1.1	66
131	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	0.5	156
132	Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. <i>Supportive Care in Cancer</i> , 2016, 24, 1789-1793.	1.0	34
133	Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. <i>Cancer</i> , 2016, 122, 50-60.	2.0	37
134	Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. <i>Oncogene</i> , 2016, 35, 459-467.	2.6	11
135	Phosphorylated Bcl-2 and Mcl-1 as prognostic markers in small cell lung cancer. <i>Oncotarget</i> , 2016, .	0.8	5
136	Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1142-1147.	0.5	19
137	Development and testing of a tool to assess patient preferences for phase I clinical trial participation. <i>Psycho-Oncology</i> , 2015, 24, 835-838.	1.0	6
138	Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs. <i>Cancer</i> , 2015, 121, 3390-3392.	2.0	11
139	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , 2015, 6, 349-354.	0.6	0
140	GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. <i>Oncotarget</i> , 2015, 6, 8974-8987.	0.8	15
141	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 852-863.	7.7	108
142	Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. <i>Cancer Letters</i> , 2015, 364, 70-78.	3.2	40
143	Bcl2 inhibits recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation. <i>Nucleic Acids Research</i> , 2015, 43, 960-972.	6.5	19
144	Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 433-441.	0.8	45

#	ARTICLE	IF	CITATIONS
145	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1859-1868.	3.2	22
146	Minimize Toxicity or Preserve Efficacy? A Delicate Trade-Off in the Management of Older Patients With Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 534-536.	0.8	3
147	Racial disparities in squamous cell carcinoma of the oral tongue among women: A SEER data analysis. <i>Oral Oncology</i> , 2015, 51, 586-592.	0.8	43
148	A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). <i>Lung Cancer</i> , 2015, 89, 66-70.	0.9	52
149	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. <i>Molecular Aspects of Medicine</i> , 2015, 45, 55-66.	2.7	26
150	Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. <i>Contemporary Clinical Trials</i> , 2015, 43, 133-141.	0.8	16
151	Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction. <i>Cancer</i> , 2015, 121, 1772-1778.	2.0	26
152	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. <i>Lung Cancer</i> , 2015, 88, 80-84.	0.9	22
153	Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 56-62.	1.4	18
154	Atypical Carcinoid Tumor of the Lung: A Surveillance, Epidemiology, and End Results Database Analysis. <i>Journal of Thoracic Oncology</i> , 2015, 10, 479-485.	0.5	63
155	Postoperative Radiotherapy is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base. <i>Journal of Thoracic Oncology</i> , 2015, 10, 462-471.	0.5	101
156	Abstract 1317: Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients. <i>Cancer Research</i> , 2015, 75, 1317-1317.	0.4	1
157	A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease. <i>World Journal of Oncology</i> , 2015, 6, 416-420.	0.6	4
158	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2014, 120, 3940-3951.	2.0	53
159	Poly (ADP-ribose) polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. <i>Cancer Medicine</i> , 2014, 3, 1579-1594.	1.3	74
160	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. <i>Cell</i> , 2014, 159, 676-690.	13.5	2,318
161	Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study. <i>Cancer Prevention Research</i> , 2014, 7, 283-291.	0.7	62
162	Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck. <i>Head and Neck Pathology</i> , 2014, 8, 66-72.	1.3	34

#	ARTICLE	IF	CITATIONS
163	E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 171-180.	1.1	3
164	Altered Glutamine Metabolism and Therapeutic Opportunities for Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 7-15.	1.1	88
165	Current approaches to the treatment of metastatic brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 203-222.	12.5	233
166	Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials. <i>Contemporary Clinical Trials</i> , 2014, 37, 322-332.	0.8	10
167	Taxanes: vesicants, irritants, or just irritating?. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 16-20.	1.4	21
168	HPV-associated lung cancers: an international pooled analysis. <i>Carcinogenesis</i> , 2014, 35, 1267-1275.	1.3	57
169	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): A systematic review. <i>Oral Oncology</i> , 2014, 50, 888-894.	0.8	20
170	Small-molecule Bax agonists for cancer therapy. <i>Nature Communications</i> , 2014, 5, 4935.	5.8	110
171	Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. <i>Cell Death and Differentiation</i> , 2014, 21, 1160-1169.	5.0	58
172	Small Cell Lung Cancer: Therapies and Targets. <i>Seminars in Oncology</i> , 2014, 41, 133-142.	0.8	55
173	Bcl2 Induces DNA Replication Stress by Inhibiting Ribonucleotide Reductase. <i>Cancer Research</i> , 2014, 74, 212-223.	0.4	40
174	Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. <i>Cancer</i> , 2013, 119, 1503-1511.	2.0	14
175	Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. <i>Cancer</i> , 2013, 119, 2602-2610.	2.0	166
176	Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer. <i>Cancer Research</i> , 2013, 73, 5485-5496.	0.4	62
177	The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. <i>Cancer Letters</i> , 2013, 338, 229-238.	3.2	28
178	Survival Analysis of Patients With Stage I Non-Small-Cell Lung Cancer Using Clinical and DNA Repair Pathway Expression Variables. <i>Clinical Lung Cancer</i> , 2013, 14, 128-138.	1.1	3
179	CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC. <i>Clinical Cancer Research</i> , 2013, 19, 1603-1611.	3.2	21
180	Upholding the Principles of Autonomy, Beneficence, and Justice in Phase I Clinical Trials. <i>Oncologist</i> , 2013, 18, 242-244.	1.9	10

#	ARTICLE	IF	CITATIONS
181	Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer. <i>Oncologist</i> , 2013, 18, 1262-1269.	1.9	13
182	Protein Phosphatase 2A and DNA-dependent Protein Kinase Are Involved in Mediating Rapamycin-induced Akt Phosphorylation. <i>Journal of Biological Chemistry</i> , 2013, 288, 13215-13224.	1.6	47
183	Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2200-2212.	1.9	137
184	Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis. <i>Oncologist</i> , 2013, 18, 600-610.	1.9	33
185	A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. <i>British Journal of Cancer</i> , 2013, 108, 762-765.	2.9	22
186	Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 369-372.	0.5	37
187	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e395-e401.	1.8	67
188	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e395-e401.	1.8	51
189	Interactive Software - Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS [®]) - for Cancer Phase I Clinical Trials. <i>Open Medical Informatics Journal</i> , 2013, 7, 8-17.	1.0	3
190	Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 45-56.	1.9	40
191	Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 272-280.	1.5	52
192	Rising Incidence of Mucosal Melanoma of the Head and Neck in the United States. <i>Journal of Skin Cancer</i> , 2012, 2012, 1-6.	0.5	55
193	Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling. <i>Journal of Biological Chemistry</i> , 2012, 287, 257-267.	1.6	35
194	Unusual suspects: pulmonary opportunistic infections masquerading as tumor metastasis in a patient with adrenocorticotrophic hormone-producing pancreatic neuroendocrine cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 295-300.	1.4	10
195	A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 866-872.	0.5	117
196	Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth. <i>Cancer Cell</i> , 2012, 22, 585-600.	7.7	329
197	NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKC ¹ /FAK loop. <i>Cancer Letters</i> , 2012, 318, 106-113.	3.2	53
198	Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2012, 77, 331-338.	0.9	51

#	ARTICLE	IF	CITATIONS
199	The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. <i>Cancer Letters</i> , 2012, 325, 139-146.	3.2	54
200	c-Myc Suppression of DNA Double-strand Break Repair. <i>Neoplasia</i> , 2012, 14, 1190-IN35.	2.3	48
201	Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. <i>Cancer</i> , 2012, 118, 4571-4578.	2.0	119
202	Adenoid cystic carcinoma of the head and neck. <i>Cancer</i> , 2012, 118, 4444-4451.	2.0	251
203	Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2012, 118, 164-172.	2.0	35
204	A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2576-2576.	0.8	2
205	The Combination of RAD001 and NVP-BE235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo. <i>PLoS ONE</i> , 2011, 6, e20899.	1.1	64
206	Oncogenic role of EAP11 in lung cancer development and its activation of the MAPK-ERK pathway. <i>Oncogene</i> , 2011, 30, 3802-3812.	2.6	35
207	Lung cancer: New biological insights and recent therapeutic advances. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 91-112.	157.7	413
208	Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data. <i>BioMedical Engineering OnLine</i> , 2011, 10, 97.	1.3	13
209	Gender and Ethnic Disparities in Incidence and Survival of Squamous Cell Carcinoma of the Oral Tongue, Base of Tongue, and Tonsils: A Surveillance, Epidemiology and End Results Program-Based Analysis. <i>Oncology</i> , 2011, 81, 12-20.	0.9	96
210	Augmentation of NVP-BE235's anticancer activity against human lung cancer cells by blockage of autophagy. <i>Cancer Biology and Therapy</i> , 2011, 12, 549-555.	1.5	56
211	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 3903-3909.	2.0	36
212	Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. <i>International Journal of Cancer</i> , 2010, 126, 743-755.	2.3	84
213	Maintenance Therapy for Advanced Non-small Cell Lung Cancer: Current Status, Controversies, and Emerging Consensus. <i>Clinical Cancer Research</i> , 2010, 16, 2496-2504.	3.2	28
214	What is the role of maintenance therapy in the treatment of non-small cell lung cancer?. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 229-235.	1.4	3
215	Abstract 5428: Histone deacetylase (HDAC) enzyme inhibition potentiates taxanes and doxorubicin activity in thyroid cancer cell lines. , 2010, , .		0
216	Lung cancer in the elderly: what's age got to do with it?. <i>Oncology</i> , 2010, 24, 1120, 1122, 1129.	0.4	0

#	ARTICLE	IF	CITATIONS
217	The Role of Cetuximab in the Management of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 230-238.	1.1	11
218	Preoperative therapy for early-stage NSCLC: opportunities and challenges. <i>Oncology</i> , 2009, 23, 886, 889, 892.	0.4	2
219	The Role of Targeted Agents in the Treatment of Elderly Patients with Non-Small Cell Lung Cancer (NSCLC). <i>Current Treatment Options in Oncology</i> , 2008, 9, 313-325.	1.3	4
220	Small Cell Lung Cancer in Elderly Patients: A Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 333-344.	2.3	12
221	Minimal progress, potential promise in small-cell lung cancer. <i>Oncology</i> , 2008, 22, 1495-6.	0.4	1
222	Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database. <i>Journal of Clinical Oncology</i> , 2007, 25, 5570-5577.	0.8	488
223	Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 491-495.	4.3	44
224	Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. <i>Biological Psychiatry</i> , 2004, 55, 766-771.	0.7	49
225	In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. <i>Journal of Nuclear Medicine</i> , 2004, 45, 94-100.	2.8	27
226	Intratumoral Genetic Heterogeneity in Barrett Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 558-566.	0.4	30
227	Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. <i>Journal of Nuclear Medicine</i> , 2002, 43, 678-92.	2.8	81
228	Comparative analysis of basaloid and typical squamous cell carcinoma of the oesophagus: a molecular biological and immunohistochemical study. <i>Journal of Pathology</i> , 2001, 193, 155-161.	2.1	35